$CALY

Five Things You Need To Know About The Acushnet and Callaway Q1 Financials

This article analyzes the Q1 2026 financial statements for Acushnet and Callaway, highlighting Callaway's renewed focus on golf after divesting Topgolf and its strong sales and net income. It also examines Acushnet's solid golf equipment and ball sales, despite ongoing challenges with FootJoy, and notes both companies' optimistic outlooks for the rest of the year. The piece compares their differing sales strengths in golf clubs versus golf balls and their respective stock performances.

Original reporting
MyGolfSpy · John Barba
Published May 12, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 12, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Five Things You Need To Know About The Acushnet and Callaway Q1 Financials — source image
Decision brief

The 30-second read

$CALYNeutralLow
01

Why it matters

Financial results reinforce sector stability; however, market sentiment remains cautious.

02

Market read

Sector showing resilience with positive financials; limited immediate trading opportunities but supportive of sector stability.

03

What to watch

Potential impact of macroeconomic factors on discretionary spending and golf industry demand.

Relevance 6/10Timing: short-term

Background

The golf industry is experiencing renewed interest post-pandemic, with companies focusing on core products.

Company-level read

Ticker impact

$CALYNeutralMedium confidence
Context

Low relevance due to minimal market impact indicated by low relevance score.

Expected impact

Likely negligible short-term price movement; long-term outlook remains cautiously optimistic.

Evidence & confidence

Financials are solid, but market reaction is muted, and stock sentiment remains neutral, indicating limited trading action.

Market effects

Positive outlook for golf equipment and accessories sector; potential slight uplift in related stocks.

Limited regional impact; primarily US-based companies with global sales influence.

Moderate; reflects sector-specific trends rather than broad market movements.

Counterpoint

Market may have already priced in strong Q1 results; upcoming quarters could reveal challenges.

Key entities

  • Acushnet

    Golf equipment manufacturer known for Titleist products.

  • Callaway

    Golf equipment and apparel company, focusing on golf clubs and balls.

Related articles

Med

Truist raises Callaway Golf stock price target on self-help factors

Truist Securities raised its price target for Callaway Golf (NYSE:ELY) to $20.00 from $19.00, citing self-help factors like SKU rationalization and store closures. The stock is up 64% over the past year. Callaway reported Q2 2026 earnings of $0.39 per share, beating estimates, with revenue of $612.2 million and a 36% increase in adjusted EBITDA.

$CALYMed

CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS

Callaway Golf Co (CALY) filed an SEC Form 8-K — Results of Operations and Financial Condition. CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS Second Quarter Net Sales (+2%), GAAP Net Income from Continuing Operations (+67%) and Adjusted EBITDA (+36%) Raises Full-Year Guidance HIGHLIGHTS • Q2 GAAP and Non-GAAP Gross Margin increased 620 basis points and 460 bas

$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.